Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Saved in:
| Title: | Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. |
|---|---|
| Authors: | Rossing P; Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Anker SD; Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité-Universitätsmedizin, Berlin, Germany., Filippatos G; School of Medicine, National and Kapodistrian University of Athens, Department of Cardiology, Attikon University Hospital, Athens, Greece., Pitt B; Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI., Ruilope LM; Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research Imas12, Madrid, Spain.; CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain.; Faculty of Sport Sciences, European University of Madrid, Madrid, Spain., Birkenfeld AL; German Center for Diabetes Research (DZD), München-Neuherberg, Germany.; Department of Internal Medicine, Division of Diabetology, Endocrinology, and Nephrology, and Institute of Diabetes Research and Metabolic Diseases (IDM), Helmholtz Center Munich and University Hospital Tübingen, Tübingen, Germany., McGill JB; Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, St. Louis, MO., Rosas SE; Kidney and Hypertension Unit, Joslin Diabetes Center and Harvard Medical School, Boston, MA.; Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA., Joseph A; Cardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany., Gebel M; Statistics and Data Insights, Bayer AG, Wuppertal, Germany., Roberts L; Clinical Development, Bayer PLC, Reading, U.K., Scheerer MF; Medical Affairs and Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany., Bakris GL; Department of Medicine, University of Chicago Medicine, Chicago, IL., Agarwal R; Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, IN. |
| Corporate Authors: | FIDELIO-DKD and FIGARO-DKD Investigators |
| Source: | Diabetes care [Diabetes Care] 2022 Dec 01; Vol. 45 (12), pp. 2991-2998. |
| Publication Type: | Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print Cited Medium: Internet ISSN: 1935-5548 (Electronic) Linking ISSN: 01495992 NLM ISO Abbreviation: Diabetes Care Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
